Darunavir: a review of its use in the management of HIV-1 infection
ED Deeks - Drugs, 2014 - Springer
The latest HIV-1 protease inhibitor (PI) darunavir (Prezista™) has a high genetic barrier to
resistance development and is active against wild-type HIV and HIV strains no longer …
resistance development and is active against wild-type HIV and HIV strains no longer …
[图书][B] Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach-2010 revision
World Health Organization - 2010 - apps.who.int
2010 revision Page 1 ANTIRETROVIRAL ThERApy fOR hIV INfEcTION IN INfANTs ANd
chILdREN: TOwARds uNIVERsAL AccEss Recommendations for a public health approach 2010 …
chILdREN: TOwARds uNIVERsAL AccEss Recommendations for a public health approach 2010 …
Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir
TN Kakuda, A Brochot, FL Tomaka… - Journal of …, 2014 - academic.oup.com
The ability to dose antiretroviral agents once daily simplifies the often complex therapeutic
regimens required for the successful treatment of HIV infection. Thus, once-daily dosing can …
regimens required for the successful treatment of HIV infection. Thus, once-daily dosing can …
Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: forty-eight-week results from IMPAACT P1093
RM Viani, C Alvero, T Fenton, EP Acosta… - The Pediatric …, 2015 - journals.lww.com
Objective: To assess the pharmacokinetics (PK), safety and efficacy of dolutegravir plus
optimized background regimen in HIV-infected treatment-experienced adolescents …
optimized background regimen in HIV-infected treatment-experienced adolescents …
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1–infected children aged 2 through 18 years
S Nachman, N Zheng, EP Acosta… - Clinical infectious …, 2014 - academic.oup.com
Background. IMPAACT P1066 is a phase I/II open-label multicenter trial to evaluate
pharmacokinetics, safety, tolerability, and efficacy of multiple raltegravir formulations in …
pharmacokinetics, safety, tolerability, and efficacy of multiple raltegravir formulations in …
Efficacy and Safety of Darunavir/Ritonavir at 48 Weeks in Treatment-naïve, HIV-1–infected Adolescents: Results From a Phase 2 Open-label Trial (DIONE)
P Flynn, S Komar, S Blanche, C Giaquinto… - The Pediatric …, 2014 - journals.lww.com
Background: Twice-daily darunavir/ritonavir is indicated in treatment-experienced children
(≥ 3 years). This study assessed once-daily administration in treatment-naïve adolescents …
(≥ 3 years). This study assessed once-daily administration in treatment-naïve adolescents …
Optimizing pediatric dosing recommendations and treatment management of antiretroviral drugs using therapeutic drug monitoring data in children living with HIV
H Waalewijn, A Turkova, N Rakhmanina… - Therapeutic drug …, 2019 - journals.lww.com
Methods: A PubMed search was conducted for the literature on ARV dosing published in
English. In addition, the registration documentation of European Medicines Agency and the …
English. In addition, the registration documentation of European Medicines Agency and the …
Pharmacokinetic optimization of antiretroviral therapy in children and adolescents
M Neely, NY Rakhmanina - Clinical pharmacokinetics, 2011 - Springer
There are over 2.1 million HIV-infected children worldwide, who are increasingly exposed to
antiretroviral therapy. Given the enormous physiological changes associated with …
antiretroviral therapy. Given the enormous physiological changes associated with …
Pediatric response to second-line antiretroviral therapy in South Africa
BC Zanoni, H Sunpath, ME Feeney - PloS one, 2012 - journals.plos.org
Background With improved access to pediatric antiretroviral therapy (ART) in resource-
limited settings, more children could experience first-line ART treatment failure. Methods We …
limited settings, more children could experience first-line ART treatment failure. Methods We …
Safety and efficacy of darunavir/ritonavir in treatment-experienced pediatric patients: week 48 results of the ARIEL trial
A Violari, R Bologna, N Kumarasamy… - The Pediatric …, 2015 - journals.lww.com
Background: ARIEL (Darunavir in treatment-experienced pediatric population) was a phase
II, open-label study assessing safety and antiviral activity of darunavir/ritonavir twice daily …
II, open-label study assessing safety and antiviral activity of darunavir/ritonavir twice daily …